ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,615.35
      0.55%
      US Tech 100
      19,804.00
      0.64%
      Dow Jones
      40,000.90
      0.62%
      Brent Oil
      84.57
      0.00%
      Bitcoin
      58,855.56
      1.67%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. TCR2 Therapeutics Inc (TCRR)

      7. TCR2 Therapeutics Inc (TCRR) News

      TCRR

      TCR2 Therapeutics (TCRR)

      TCR2 Therapeutics Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:TCRR
      DateTimeSourceHeadlineSymbolCompany
      12/19/20225:17PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:TCRRTCR2 Therapeutics Inc
      12/19/20225:14PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:TCRRTCR2 Therapeutics Inc
      12/19/20225:07PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:TCRRTCR2 Therapeutics Inc
      12/09/20224:44PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:TCRRTCR2 Therapeutics Inc
      12/09/20224:43PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:TCRRTCR2 Therapeutics Inc
      12/01/20224:15PMGlobeNewswire Inc.TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:TCRRTCR2 Therapeutics Inc
      11/23/20226:45AMGlobeNewswire Inc.TCR² Therapeutics to Present at the Piper Sandler Healthcare ConferenceNASDAQ:TCRRTCR2 Therapeutics Inc
      11/18/20224:40PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:TCRRTCR2 Therapeutics Inc
      11/18/20224:40PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:TCRRTCR2 Therapeutics Inc
      11/18/20224:08PMEdgar (US Regulatory)Amended Tender Offer Statement by Issuer (sc To-i/a)NASDAQ:TCRRTCR2 Therapeutics Inc
      11/09/20223:25AMTipRanksMizuho Securities Sticks to Their Buy Rating for TCR2 Therapeutics (TCRR)NASDAQ:TCRRTCR2 Therapeutics Inc
      11/08/202211:36AMTipRanksSVB Securities Keeps Their Hold Rating on TCR2 Therapeutics (TCRR)NASDAQ:TCRRTCR2 Therapeutics Inc
      11/08/20227:17AMEdgar (US Regulatory)Quarterly Report (10-q)NASDAQ:TCRRTCR2 Therapeutics Inc
      11/08/20227:01AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:TCRRTCR2 Therapeutics Inc
      11/08/20226:45AMGlobeNewswire Inc.TCR² Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateNASDAQ:TCRRTCR2 Therapeutics Inc
      11/07/20228:01AMGlobeNewswire Inc.TCR² Therapeutics Presents Preclinical Data on Functional Activity of Gavo-cel at the Society for Immunotherapy of CancerNASDAQ:TCRRTCR2 Therapeutics Inc
      11/01/20224:15PMGlobeNewswire Inc.TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:TCRRTCR2 Therapeutics Inc
      10/19/20224:16PMEdgar (US Regulatory)Tender Offer Statement by Issuer (sc To-i)NASDAQ:TCRRTCR2 Therapeutics Inc
      10/14/20224:18PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:TCRRTCR2 Therapeutics Inc
      10/03/20224:20PMGlobeNewswire Inc.TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:TCRRTCR2 Therapeutics Inc
      09/29/20226:25AMTipRanksTCR2 Therapeutics (TCRR) Gets a Buy from H.C. WainwrightNASDAQ:TCRRTCR2 Therapeutics Inc
      09/28/202212:40PMTipRanksAnalysts Offer Insights on Healthcare Companies: Ocugen (OCGN), 9 Meters Biopharma (NMTR) and TCR2 Therapeutics (TCRR)NASDAQ:TCRRTCR2 Therapeutics Inc
      09/28/20227:02AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:TCRRTCR2 Therapeutics Inc
      09/28/20226:45AMGlobeNewswire Inc.gavo-cel Continues to Demonstrate Clinical Benefit in Solid Tumors with Additional RECIST Reponses in Ovarian Cancer and MesotheliomaNASDAQ:TCRRTCR2 Therapeutics Inc
      09/27/20224:15PMGlobeNewswire Inc.TCR² Therapeutics to Announce Complete Phase 1 Portion of the Gavo-cel Phase 1/2 Clinical Trial for Mesothelin-Expressing Solid TumorsNASDAQ:TCRRTCR2 Therapeutics Inc
      09/26/20224:15PMGlobeNewswire Inc.TCR² Therapeutics to Present at the Jefferies Cell & Genetic Medicine SummitNASDAQ:TCRRTCR2 Therapeutics Inc
      09/16/20224:24PMTipRanksTCR2 Therapeutics management to meet with TruistNASDAQ:TCRRTCR2 Therapeutics Inc
      09/01/20225:15PMGlobeNewswire Inc.TCR2 Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:TCRRTCR2 Therapeutics Inc
      09/01/20224:09PMEdgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:TCRRTCR2 Therapeutics Inc
      09/01/20224:07PMEdgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:TCRRTCR2 Therapeutics Inc
       Showing the most relevant articles for your search:NASDAQ:TCRR